Development of the new therapeutic approach targeting IL-13Ralpha2 in pancreatic ductal adenocarcinoma.

• Project/Area Number: 25870846
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Tumor therapeutics; Gastroenterology
• Research Institution: Juntendo University (2016); Tokyo Health Care University (2013-2015)
• Principal Investigator: Fujisawa Toshio 順天堂大学, 医学部, 准教授 (50627346)
• Research Collaborator: NAKAJIMA Atsushi 横浜市立大学, 医学部, 教授 ; PURI Raj, K US Food and Drug Administration, Center for Biologics Evluation and Research Organization, Department director
• Project Period (FY): 2013-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: IL-13Ralpha2 / 膵臓癌 / 浸潤 / 転移 / 生命予後 / ポリフェノール / 神経浸潤 / HAT阻害薬 / Epigallocatechin gallate / IL-13Rα2 / HAT inhibitor / 膵臓癌マウスモデル / 予後規定因子 / IL13Ralpha2 / 国際情報交換(アメリカ) / エピジェネティクス / 転移抑制 / 国際情報交換

Outline of Final Research Achievements

We examined the relationship between the expression of IL-13Ralpha2 and survival time using the surgically resected samples of pancreatic cancer. Totally, 236 samples were examined, and they indicated that IL-13Ralpha2-high expresser showed significantly short survival time. Furthermore, IL-13Ralpha2 could enhance invasion to the nerve, because the expression of IL-13Ralpha2 showed strong correlation with the perineural invasion.
Then, we examined the cancer therapy targeting IL-13Ralpha2. Epigallocatechin gallate (EGCG) included in the green tea suppressed the expression of IL-13Ralpha2 in the pancreatic cancer cells. Orally administered ECGC extended the survival time of the host in the model mouse of pancreatic cancer.

Research Products

• [Int'l Joint Research] Food and Drug Administration(米国)
• [Int'l Joint Research] US Food and Drug Administration(米国)
• [Journal Article] Obesity with Abundant Subcutaneous Adipose Tissue Increases the Risk of post-ERCP pancreatitis (2016)
  • Author(s): Toshio Fujisawa, Koichi Kagawa, Kantaro Hisatomi, Kensuke Kubota, Hajime Sato, Atsushi Nakajima, Nobuyuki Matsuhashi
  • Journal Title: Journal of Gastroenterology Volume: ePub first
  • Peer Reviewed
• [Journal Article] Prophylactic Efficacy of 3- or 5-cm Pancreatic Stents for Preventing Post-ERCP Pancreatitis: A Prospective, Randomized Trial (2016)
  • Author(s): Fujisawa T, Kagawa K, Ochiai K, Hisatomi K, Kubota K, Sato H, Nakajima A, Matsuhashi N.
  • Journal Title: Journal of Clinical Gastroenterology Volume: 50 Issue: 3 Pages: e30-e34
  • DOI: 10.1097/mcg.0000000000000397
  • Peer Reviewed
• [Journal Article] Pancreatic paraganglioma with draining vessels (2015)
  • Author(s): Misumi Y, Fujisawa T, Hashimoto H, Kagawa K, Noie T, Chiba H, Horiuchi H, Harihara Y, Matsuhashi N.
  • Journal Title: World Journal of Gastroenterology Volume: 21 Issue: 31 Pages: 9442-9447
  • DOI: 10.3748/wjg.v21.i31.9442
  • Peer Reviewed / Open Access
• [Presentation] 膵臓癌におけるIL-13Ra2の予後規定因子と治療標的としての可能性 (2016)
  • Author(s): 藤澤聡郎
  • Organizer: 第１０２回日本消化器病学会総会
  • Place of Presentation: 東京
  • Year and Date: 2016-04-21
• [Presentation] 膵臓癌におけるIL-13Ra2の予後規定因子と治療標的としての可能性 (2016)
  • Author(s): 藤澤 聡郎, 中島 淳, 松橋 信行
  • Organizer: 第102回日本消化器病学会総会
  • Place of Presentation: 京王プラザホテル, 東京
  • Year and Date: 2016-04-21
• [Presentation] Overexpressed Interleukin-13 Receptor α2 Shorten Survival Time in Surgically Resected Pancreatic Cancer Patients (2015)
  • Author(s): Toshio Fujisawa, Takeshi Shimamura, Joshi H. Bharat, Raj K. Puri
  • Organizer: Annual meeting of Society for Immunotherapy of Cancer
  • Place of Presentation: Maryland, USA
  • Year and Date: 2015-11-05
  • Int'l Joint Research